½ÃÀ庸°í¼­
»óǰÄÚµå
1587801

À¯¸®È­ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Ç¥º»º°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)

Vitrification Market Size, Share & Trends Analysis Report, By Specimen (Oocytes, Embryo, Sperm), By End Use (IVF Clinics, Biobanks), By Region (North America, Europe, Asia Pacific), And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

À¯¸®È­ ½ÃÀå ¼ºÀå°ú µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, ¼¼°è À¯¸®È­ ½ÃÀå ±Ô¸ð´Â 2025³âºÎÅÍ 2030³â±îÁö 17.09%ÀÇ CAGR·Î 2030³â±îÁö 242¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

À¯¸®È­ÀÇ °³¹ß¿¡ ¹ÚÂ÷¸¦ °¡ÇÑ °ÍÀº ºÒÀÓ Ä¡·áÀÇ º¸Á¸ ¹æ¹ýÀÇ ¹ßÀüÀÔ´Ï´Ù. ÀÌ Çõ½ÅÀûÀÎ ±â¼úÀº º¸Á¸ ±â°£À» ´ÜÃàÇÒ »Ó¸¸ ¾Æ´Ï¶ó µ¿°á º¸È£Á¦¿¡ ´ëÇÑ ³ëÃâÀ» ÁÙÀÌ´Â ½Ã·á º¸Á¸ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·Î ÀÎÇØ À¯¸®È­ ÀåºñÀÇ Ã¤ÅÃÀÌ °¡¼ÓÈ­µÇ¾î ½ÃÀå ¼öÀÍ ¼ºÀåÀ¸·Î À̾îÁ³½À´Ï´Ù. Ãâ»ê Áö¿¬Àº ÁÖ·Î °æ·Â/±³À° ¸ñÇ¥, ¿©¼º ÁöÀ§ Çâ»ó ¿îµ¿ÀÇ ¿µÇâ·Â Áõ°¡, ÆÄÆ®³Ê ºÎÁ·, °æÁ¦Àû À庮°ú °°Àº »çȸ Àα¸Åë°èÇÐÀû Ãø¸é°ú °ü·ÃÀÌ ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ÀÌÀ¯ÀÔ´Ï´Ù. ¿©·¯ ¿¬±¸¿¡ µû¸£¸é 30-40¼¼±îÁö Àڳฦ °®Áö ¾Ê´Â °¡Àå ÈçÇÑ ÀÌÀ¯´Â ÀûÀýÇÑ ÆÄÆ®³Ê°¡ ¾ø±â ¶§¹®ÀÎ °ÍÀ¸·Î º¸°íµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ CDCÀÇ º¸°í¼­¿¡ µû¸£¸é ¹Ì±¹¿¡¼­ ¿©¼ºÀÌ Ã¹ ¾ÆÀ̸¦ ³º´Â Æò±Õ ¿¬·ÉÀÌ Áö³­ ¼ö½Ê ³âº¸´Ù ³ô¾ÆÁ³´Ù°í ÇÕ´Ï´Ù. ¶ÇÇÑ 2023³â 1¿ù¿¡ ¹ßÇ¥µÈ CDCÀÇ 'National Health Statistics Report'¶ó´Â Á¦¸ñÀÇ º¸°í¼­¿¡ µû¸£¸é 2015-2019³â 15-44¼¼ ¿©¼º°ú ³²¼ºÀÇ Æò±Õ ÃÊ»ê ¿¬·ÉÀº °¢°¢ 23.7¼¼¿Í 26.4¼¼·Î, 2011-2015³âÀÇ Æò±Õ ÃÊ»ê ¿¬·Éº¸´Ù ³ô½À´Ï´Ù. ÀÇ ¿©¼º°ú ³²¼ºÀÇ Æò±Õ ÃÊ»ê ¿¬·Éº¸´Ù ³ôÀº °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¶ÇÇÑ, ºñÈ÷½ºÆÐ´Ð°è ¾Æ½Ã¾Æ ¿©¼ºÀÇ Æò±Õ ÃÊ»ê ¿¬·ÉÀÌ 28.4¼¼·Î °¡Àå ³ô¾Ò½À´Ï´Ù. ÀÌ·Î ÀÎÇØ °í·É ºÒÀÓ ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇØ ³­ÀÚ ¹× Á¤ÀÚ º¸Á¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖÀ¸¸ç, CDC¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â 15¼¼¿¡¼­ 44¼¼ »çÀÌÀÇ ¾à 610¸¸ ¸íÀÇ ¿©¼ºÀÌ ÀÓ½ÅÀ» Áö¼ÓÇϰųª Àӽй®Á¦¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ IVF Australia¿¡ µû¸£¸é È£ÁÖÀÇ ¾à 16.66%ÀÇ ºÎºÎ°¡ °¡ÀÓ ¿¬·É¿¡ ºÒÀÓÀÌ ÀÖ´Ù°íÇÕ´Ï´Ù.

ÀÌ·¯ÇÑ ºÒÀÓÀÇ Áõ°¡´Â °¡ÀÓ·Â º¸Á¸ ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½ÃÄÑ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸¹Àº ±¹°¡¿¡¼­ µ¿¼º°áÈ¥ÀÇ ¹ýÀû ½ÂÀΰú ¹ÌÈ¥¸ð Áõ°¡·Î ÀÎÇØ ³­ÀÚ ¹× Á¤ÀÚ µ¿°áº¸Á¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ¿¡ µû¶ó À¯¸®È­ ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀϺ»°ú °°Àº ±¹°¡¿¡¼­´Â ³­ÀÚ µ¿°áÀ» ¿øÇÏ´Â ¿©¼º¿¡°Ô ±ÝÀüÀû Áö¿øÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ¾ÏÇùȸ¿¡ µû¸£¸é, Àü¹®°¡µéÀº ¾Ï ¿©¼ºµéÀÌ °¡ÀÓ·ÂÀ» À¯ÁöÇϱâ À§ÇØ ³­ÀÚ µ¿°áÀ̳ª ¹è¾Æ µ¿°áÀ» ±ÇÀåÇϰí ÀÖÀ¸¸ç, ÀÌ´Â °¡ÀÓ·Â º¸Á¸ ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í ³ôÀ̰í ÀÖ½À´Ï´Ù. ÀÌ´Â °¡ÀÓ·Â º¸Á¸ÀÌ »çȸÀûÀ¸·Î ¼ö¿ëµÇ°í ÀÖÀ½À» º¸¿©ÁÖ´Â ÁöÇ¥·Î, Àüü ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª °¡ÀÓ·Â º¸Á¸ ÇÁ·ÎÅäÄÝ ¹× ½Ã¼ú°ú °ü·ÃµÈ À§ÇèÀº ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

À¯¸®È­ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • °Ëüº°·Î´Â ³­ÀÚ ºÎ¹®ÀÌ 2024³â 42.09%·Î °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ¹æ¹ýÀÇ È¿°ú´Â Ãâ»ý¾Æ ¼ö Áõ°¡¿Í ÇÔ²² ³­ÀÚ »ýÁ¸À²°ú ÀÓ½ÅÀ²ÀÇ Áõ°¡·Î ÀÔÁõµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ³­ÀÚ À¯¸®È­ ±â¼úÀÇ ¹ßÀüÀº ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ü¿Ü¼öÁ¤ Ŭ¸®´ÐÀÇ ÃÖÁ¾ »ç¿ë ºÎ¹®Àº ÀÌ·¯ÇÑ ÃÖÁ¾ »ç¿ë ȯ°æ¿¡¼­ Àåºñ ¹× ¼Ò¸ðǰÀÇ ±¤¹üÀ§ÇÑ »ç¿ëÀ¸·Î ÀÎÇØ 2024³â 59.76%ÀÇ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. À¯¸®È­ ±â¼úÀº IVF ¼º°ø·ü°ú ³­ÀÚ ¹× ¹è¾Æ µ¿°á Áֱ⠼ö Ãø¸é¿¡¼­ »ý½Ä ÀÇÇÐ ºÐ¾ß¸¦ Å©°Ô °­È­Çß½À´Ï´Ù.
  • À¯·´Àº 2024³â 39.63%·Î °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â ÁÖ·Î º¸Á¶»ý½Ä¼ú(ART) ºÐ¾ß¿¡ ´ëÇÑ ¼ö³â°£ÀÇ Âü¿©¿¡ ±âÀÎÇÕ´Ï´Ù. ÀÌ Áö¿ªÀÇ ¿¹»ó ¼öÀÍ Á¡À¯À²Àº À¯·´ Àü¿ª¿¡ ¸¹Àº ´ë±â¾÷ÀÌ Á¸ÀçÇϱ⠶§¹®À̱⵵ ÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óºÎ ½ÃÀå Àü¸Á
    • °ü·Ã/º¸Á¶ ½ÃÀå Àü¸Á
  • ½ÃÀå µ¿Çâ°ú Àü¸Á
    • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ºñÁî´Ï½º ȯ°æ ºÐ¼®
    • PESTEL ºÐ¼®
    • Porter's Five Forces ºÐ¼®
    • COVID-19ÀÇ ¿µÇ⠺м®
  • µð¹ÙÀ̽º º¥Ä¡¸¶Å©

Á¦4Àå °Ëü ºñÁî´Ï½º ºÐ¼®

  • °Ëü ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ À¯¸®È­ ½ÃÀå : °Ëü º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ À¯¸®È­ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, °Ëüº°, 2018-2030³â
  • ³­¸ð¼¼Æ÷
    • ³­¸ð¼¼Æ÷ ½ÃÀå, 2018-2030³â
    • µð¹ÙÀ̽º
    • ŰƮ¿Í ¼Ò¸ðǰ
  • ¹è
    • ¹è ½ÃÀå, 2018-2030³â
    • µð¹ÙÀ̽º
    • ŰƮ¿Í ¼Ò¸ðǰ
  • Á¤ÀÚ
    • Á¤ÀÚ ½ÃÀå, 2018-2030³â

Á¦5Àå ÃÖÁ¾ ¿ëµµ ºñÁî´Ï½º ºÐ¼®

  • ÃÖÁ¾ ¿ëµµ ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ À¯¸®È­ ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ À¯¸®È­ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, Á¦Ç°º°, 2018-2030³â
  • ü¿Ü¼öÁ¤ Ŭ¸®´Ð
    • ü¿Ü¼öÁ¤ Ŭ¸®´Ð ½ÃÀå, 2018-2030³â
  • ¹ÙÀÌ¿À¹ðÅ©
    • ¹ÙÀÌ¿À¹ðÅ© ½ÃÀå, 2018-2030³â

Á¦6Àå Áö¿ª ºñÁî´Ï½º ºÐ¼®

  • Áö¿ª ´ë½Ãº¸µå
  • Áö¿ªº° ¼¼°èÀÇ À¯¸®È­ ½ÃÀå Á¡À¯À², 2024³â°ú 2030³â
  • ºÏ¹Ì
    • ºÏ¹ÌÀÇ À¯¸®È­ ½ÃÀå, 2018-2030³â
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • À¯·´ÀÇ À¯¸®È­ ½ÃÀå, 2018-2030³â
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯¸®È­ ½ÃÀå, 2018-2030³â
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ À¯¸®È­ ½ÃÀå, 2018-2030³â
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« À¯¸®È­ ½ÃÀå, 2018-2030³â
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦7Àå °æÀï »óȲ

  • ±â¾÷ ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ ½ÃÀå »óȲ ºÐ¼®, 2024³â
  • ±â¾÷ °³¿ä/»óÀå ±â¾÷
    • Vitrolife
    • Genea Biomedx
    • NidaCon International AB
    • Minitube
    • IMV TECHNOLOGIES GROUP(Cryo Bio System)
    • The Cooper Companies, Inc.(A CooperSurgical Fertility Company)
    • FUJIFILM Corporation(FUJIFILM Irvine Scientific)
    • Biotech, Inc.
    • Kitazato Corporation
    • Shenzhen VitaVitro Biotech
ksm 24.11.25

Vitrification Market Growth & Trends:

The global vitrification market size is expected to reach USD 24.25 billion by 2030, registering a CAGR of 17.09% from 2025 to 2030, according to a new report by Grand View Research, Inc. The development of vitrification was spurred by advancements in fertility preservation procedures. This innovative technology provides specimen preservation solutions that not only shorten preservation time but also reduce exposure to cryoprotectants. This has accelerated the adoption of vitrification devices, resulting in the market's profitable revenue growth. Delaying parenthood is primarily coupled with sociodemographic aspects, including career/education goals, the rising influence of women's empowerment movements, lack of a partner, and financial barriers, which are the primary reasons for driving the market growth. Several studies have reported a lack of a suitable partner as the most common reason for not having a child till the age of 30 to 40 years.

In addition, as per a CDC report, in the U.S., the average age of women having their first child has increased over previous decades. Moreover, a CDC report titled National Health Statistics Report, published in January 2023, showed that the average age at first birth for women and men aged between 15 and 44 years in 2015-2019 was 23.7 & 26.4, respectively, which was higher than the average age at first birth for women and men in 2011-2015. In addition, the average age at first birth was found to be the highest for non-Hispanic Asian women, which was 28.4. This has increased the demand to preserve oocytes and sperm to address infertility issues at older ages and further propels the market growth. According to the CDC, around 6.1 million women in the U.S. aged between 15 and 44 years face issues staying or getting pregnant. Moreover, according to IVF Australia, around 16.66% of couples in Australia have infertility in their reproductive age.

The increasing cases of infertility further propels the demand for fertility preservation services and drives market growth. In addition, legal endorsement of same-sex marriage and a rise in single parenthood in numerous nations have raised the demand for cryopreservation of eggs & sperm, resulting in increased demand for vitrification services. Countries, such as Japan, are providing financial help to women seeking egg freezing. According to the American Cancer Society, experts recommend egg freezing or embryo freezing to women with cancer to preserve fertility, further increasing the demand for fertility preservation services. These are indicators of increased acceptance of fertility preservation in society, which are driving the overall market growth. However, risks associated with fertility preservation protocols and procedures are anticipated to hamper the market growth to a considerable extent.

Vitrification Market Report Highlights:

  • By specimen, the oocytes segment accounted for the largest share of 42.09% in 2024. The efficacy of the method has been proven by increased rates of oocyte survival and pregnancies, along with increased live births. Such advancements in oocyte vitrification techniques are anticipated to drive the segment growth.
  • The IVF clinics end-use segment accounted for the largest share of 59.76% in 2024 due to the extensive utilization of equipment and supplies in these end-use settings. Vitrification technology has substantially enhanced the reproductive health space in terms of IVF success rate and the number of freezing cycles for oocytes & embryos.
  • Europe held the largest share of 39.63% in 2024. This is mostly due to its long-standing involvement in the field of Assisted Reproduction Technology (ART). The predicted revenue share of this region has also been influenced by the existence of many major companies across Europe.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Specimen Segment
    • 1.2.2. End Use Segment
  • 1.3. Research Assumptions
  • 1.4. Information Procurement
    • 1.4.1. Primary Research
  • 1.5. Information or Data Analysis
  • 1.6. Market Formulation & Validation
  • 1.7. Market Model
  • 1.8. Global Market: CAGR Calculation
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
    • 3.2.1. Market Dynamics
      • 3.2.1.1. Increase In Delayed Childbearing/Parenthood
      • 3.2.1.2. Social Acceptance Of Fertility Preservation Techniques
      • 3.2.1.3. Rising Awareness About Reproductive Health
      • 3.2.1.4. Increase In Prevalence Of Infertility And Infecundity
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Technical And Ethical Challenges Of Fertility Preservation
      • 3.2.2.2. Low Risk-Benefit Ratio
  • 3.3. Business Environment Analysis
    • 3.3.1. PESTEL Analysis
    • 3.3.2. Porter's Five Forces Analysis
    • 3.3.3. COVID-19 Impact Analysis
  • 3.4. Device Benchmarking

Chapter 4. Specimen Business Analysis

  • 4.1. Specimen Segment Dashboard
  • 4.2. Global Vitrification Market: Specimen Movement Analysis
  • 4.3. Global Vitrification Market Size & Trend Analysis, by Specimen, 2018 to 2030 (USD Million)
  • 4.4. Oocytes
    • 4.4.1. Oocytes Market, 2018 - 2030 (USD Million)
    • 4.4.2. Devices
      • 4.4.2.1. Devices Market, 2018 - 2030 (USD Million)
    • 4.4.3. Kits & Consumables
      • 4.4.3.1. Kits & Consumables Market, 2018 - 2030 (USD Million)
  • 4.5. Embryo
    • 4.5.1. Embryo Market, 2018 - 2030 (USD Million)
    • 4.5.2. Devices
      • 4.5.2.1. Devices Market, 2018 - 2030 (USD Million)
    • 4.5.3. Kits & Consumables
      • 4.5.3.1. Kits & Consumables Market, 2018 - 2030 (USD Million)
  • 4.6. Sperm
    • 4.6.1. Sperm Market, 2018 - 2030 (USD Million)

Chapter 5. End Use Business Analysis

  • 5.1. End Use Segment Dashboard
  • 5.2. Global Vitrification Market: End Use Movement Analysis
  • 5.3. Global Vitrification Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 5.4. IVF Clinics
    • 5.4.1. IVF Clinics Market, 2018 - 2030 (USD Million)
  • 5.5. Biobanks
    • 5.5.1. Biobanks Market, 2018 - 2030 (USD Million)

Chapter 6. Regional Business Analysis

  • 6.1. Regional dashboard
  • 6.2. Global Vitrification Market Share By Region, 2024 & 2030
  • 6.3. North America
    • 6.3.1. North America Vitrification Market, 2018 - 2030 (USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Competitive Scenario
      • 6.3.2.3. Regulatory Framework
      • 6.3.2.4. Target Disease Prevalence
      • 6.3.2.5. U.S. Vitrification Market, 2018 - 2030 (USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Competitive Scenario
      • 6.3.3.3. Regulatory Framework
      • 6.3.3.4. Target Disease Prevalence
      • 6.3.3.5. Canada Vitrification Market, 2018 - 2030 (USD Million)
    • 6.3.4. Mexico
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Competitive Scenario
      • 6.3.4.3. Regulatory Framework
      • 6.3.4.4. Target Disease Prevalence
      • 6.3.4.5. Mexico Vitrification Market, 2018 - 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. Europe Vitrification Market, 2018 - 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Competitive Scenario
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Target Disease Prevalence
      • 6.4.2.5. Germany Vitrification Market, 2018 - 2030 (USD Million)
    • 6.4.3. UK
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Competitive Scenario
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Target Disease Prevalence
      • 6.4.3.5. UK Vitrification Market, 2018 - 2030 (USD Million)
    • 6.4.4. France
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Competitive Scenario
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Target Disease Prevalence
      • 6.4.4.5. France Vitrification Market, 2018 - 2030 (USD Million)
    • 6.4.5. Italy
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Competitive Scenario
      • 6.4.5.3. Regulatory Framework
      • 6.4.5.4. Target Disease Prevalence
      • 6.4.5.5. Italy Vitrification Market, 2018 - 2030 (USD Million)
    • 6.4.6. Spain
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Competitive Scenario
      • 6.4.6.3. Regulatory Framework
      • 6.4.6.4. Target Disease Prevalence
      • 6.4.6.5. Spain Vitrification Market, 2018 - 2030 (USD Million)
    • 6.4.7. Denmark
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Competitive Scenario
      • 6.4.7.3. Regulatory Framework
      • 6.4.7.4. Target Disease Prevalence
      • 6.4.7.5. Denmark Vitrification Market, 2018 - 2030 (USD Million)
    • 6.4.8. Sweden
      • 6.4.8.1. Key Country Dynamics
      • 6.4.8.2. Competitive Scenario
      • 6.4.8.3. Regulatory Framework
      • 6.4.8.4. Target Disease Prevalence
      • 6.4.8.5. Sweden Vitrification Market, 2018 - 2030 (USD Million)
    • 6.4.9. Norway
      • 6.4.9.1. Key Country Dynamics
      • 6.4.9.2. Competitive Scenario
      • 6.4.9.3. Regulatory Framework
      • 6.4.9.4. Target Disease Prevalence
      • 6.4.9.5. Norway Vitrification Market, 2018 - 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Asia Pacific Vitrification Market, 2018 - 2030 (USD Million)
    • 6.5.2. Japan
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Target Disease Prevalence
      • 6.5.2.5. Japan Vitrification Market, 2018 - 2030 (USD Million)
    • 6.5.3. China
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Target Disease Prevalence
      • 6.5.3.5. China Vitrification Market, 2018 - 2030 (USD Million)
    • 6.5.4. India
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Competitive Scenario
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Target Disease Prevalence
      • 6.5.4.5. India Vitrification Market, 2018 - 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Competitive Scenario
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Target Disease Prevalence
      • 6.5.5.5. South Korea Vitrification Market, 2018 - 2030 (USD Million)
    • 6.5.6. Australia
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Competitive Scenario
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Target Disease Prevalence
      • 6.5.6.5. Australia Vitrification Market, 2018 - 2030 (USD Million)
    • 6.5.7. Thailand
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Competitive Scenario
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Target Disease Prevalence
      • 6.5.7.5. Thailand Vitrification Market, 2018 - 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Latin America Vitrification Market, 2018 - 2030 (USD Million)
    • 6.6.2. Brazil
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Target Disease Prevalence
      • 6.6.2.5. Brazil Vitrification Market, 2018 - 2030 (USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Target Disease Prevalence
      • 6.6.3.5. Argentina Vitrification Market, 2018 - 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. MEA Vitrification Market, 2018 - 2030 (USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Competitive Scenario
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Target Disease Prevalence
      • 6.7.2.5. South Africa Vitrification Market, 2018 - 2030 (USD Million)
    • 6.7.3. Saudi Arabia
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Competitive Scenario
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Target Disease Prevalence
      • 6.7.3.5. Saudi Arabia Vitrification Market, 2018 - 2030 (USD Million)
    • 6.7.4. UAE
      • 6.7.4.1. Key Country Dynamics
      • 6.7.4.2. Competitive Scenario
      • 6.7.4.3. Regulatory Framework
      • 6.7.4.4. Target Disease Prevalence
      • 6.7.4.5. UAE Vitrification Market, 2018 - 2030 (USD Million)
    • 6.7.5. Kuwait
      • 6.7.5.1. Key Country Dynamics
      • 6.7.5.2. Competitive Scenario
      • 6.7.5.3. Regulatory Framework
      • 6.7.5.4. Target Disease Prevalence
      • 6.7.5.5. Kuwait Vitrification Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Position Analysis, 2024
  • 7.4. Company Profiles/Listing
    • 7.4.1. Vitrolife
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. Genea Biomedx
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. NidaCon International AB
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Minitube
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. IMV TECHNOLOGIES GROUP (Cryo Bio System)
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. The Cooper Companies, Inc. (A CooperSurgical Fertility Company)
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. FUJIFILM Corporation (FUJIFILM Irvine Scientific)
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Biotech, Inc.
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Kitazato Corporation
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Shenzhen VitaVitro Biotech
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦